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Abstract 24 
Recent work has suggested that the activity of extracellular signal-regulated kinase 25 
(ERK) 1/2 is increased in the retinal pigment epithelium (RPE) of age-related macular 26 
degeneration (ARMD) patients and therefore could be an attractive therapeutic 27 
target. Notably, ERK1/2 pathway inhibitors are used in cancer therapy, with severe 28 
and non-characterized ocular side effects. To decipher the role of ERK1/2 in RPE 29 
cells, we conditionally disrupted the Erk1 and Erk2 genes in the mouse RPE. Loss of 30 
ERK1/2 activity resulted in a significant decrease of RPE65 expression, a decrease 31 
in ocular retinoid levels concomitant with low visual function and a rapid 32 
disorganization of RPE cells, ultimately leading to retinal degeneration. Our results 33 
identify the ERK1/2 pathway as a direct regulator of the visual cycle and a critical 34 
component for the viability of RPE and photoreceptor cells. Moreover, they caution 35 
about the need for a very fine adjustment of kinase inhibition in cancer or ARMD 36 
treatment in order to avoid the ocular side effects. 37 
Introduction 38 
ARMD is the most common cause of blindness in individuals over 50 years of age. 39 
This pathology is characterized by the presence of soft and/or hard drusen 40 
(extracellular debris and deposits), hyper- and hypo-pigmentation of retinal pigment 41 
epithelium (RPE) cells, RPE and photoreceptor apoptosis as well as choroidal 42 
neovascularization (CNV) (1). Two subgroups of ARMD can be distinguished: the 43 
dry form (geographic atrophy, GA) and the wet form (exudative). The dry form is 44 
characterized by the formation of drusen between RPE cells and Bruch’s membrane 45 
(2). This accumulation is toxic for RPE cells, altering some of their important 46 
functions. The wet form is linked to CNV affecting the subretinal macular region, 47 
which eventually results in a loss of central vision. 48 
An accumulation of intracellular lipofuscin occurs in both forms of ARMD. One of the 49 
major components of lipofuscin is the retinoid derivative, N-retinyl-N-retinylidene 50 
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ethanolamine (A2E). A2E has a broad light absorption spectrum, with a peak in the 51 
blue range (~430nm). Therefore, it is a potent photo-inducible generator of reactive 52 
oxygen species (ROS) which can damage proteins, lipids and DNA of RPE cells (3-53 
5). Even if new imaging techniques did not reveal any correlation between A2E 54 
distribution and lipofuscin fluorescence in human RPE (6), it remains unclear whether 55 
metabolites or modified forms of A2E could be deleterious for the retina and RPE; 56 
especially because A2E accumulation is linked to lipofuscin increase with age (7). 57 
Moreover, the accumulation of A2E in phagolysosomes can lead to inhibition of the 58 
turnover of endogenous proteins in cultured RPE cells by abolishing the pH gradient 59 
required for the normal function of these organelles (8). This damage leads to 60 
apoptosis and impaired RPE cell functions. In addition, previous work from our 61 
laboratory showed that A2E induces a strong decrease in extracellular signal-62 
regulated kinase (ERK) 1/2 activity in polarized ARPE19 and isolated mouse RPE 63 
cells, and inhibition of ERK1/2 leads to a significant decrease of retinal pigment 64 
epithelium-specific protein 65kDa (RPE65) (9). 65 
Mitogen-activated protein kinases (MAPKs) are evolutionarily conserved protein 66 
kinases that transduce signals to regulate gene expression during cell proliferation, 67 
survival and differentiation (10-12). There are two different groups of MAPKs: the 68 
conventional (ERK1/2/5, p38 kinases and JNK1/2/3) and the atypical (ERK3/4, 69 
ERK7 and NLK) MAPKs (13). Due to their important roles in cellular homeostasis, 70 
abnormal regulation of the conventional MAPK pathways has been linked to a wide 71 
range of diseases (12, 14-17). The ERK1/2 pathway in particular is commonly 72 
deregulated in human cancer, which has led to the development and clinical 73 
evaluation of several small molecule inhibitors targeting components of this pathway 74 
(18, 19). Notably, the clinical benefit of these molecules is limited by mechanism-75 
based side effects of blurred vision and altered light perception (20, 21). 76 
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Growing evidence indicates an important role of ERK1/2 signaling in retinal function. 77 
Retina maturation is associated with the activation of ERK1/2, which are proposed to 78 
play a survival role during development (22). We recently showed that ERK1/2 79 
activity is upregulated in RPE65-KO mice (23) and is decreased when ARPE19 cells 80 
are exposed to UV stress (24). Regeneration of the chick embryo retina was found to 81 
associated with FGF/FGFR/MEK/ERK-dependent upregulation of the paired 82 
homeobox transcription factor PAX6 in the RPE (25). Interestingly, recent clinical 83 
studies by the group of Ambati revealed the increase of ERK1/2 activity in the RPE of 84 
patients suffering from GA as well as in a mouse model of RPE degeneration 85 
induced by DICER1 depletion (26). These findings suggest a key role for ERK1/2 in 86 
ARMD and support the concept of ERK1/2 inhibition as a possible treatment of the 87 
disease (26). However, the ERK1/2 signaling pathway is complex, with multiple roles 88 
in differentiation,proliferation and cell death pathways depending on the cellular 89 
context. This complexity has been described in many studies (27, 28) and is a central 90 
question in order to understand the role of these kinases before considering to 91 
modulate its activity for therapeutic purposes. 92 
Inhibitors of the ERK1/2 pathway used in cancer therapy may provoke ocular 93 
secondary effects (21), yet this treatment is proposed for ARMD (26). In fact, little is 94 
known about the real impact of blocking these kinases in the mouse retina. 95 
Therefore, in order to obtain valuable insights about ERK1/2 inhibition and to 96 
understand the role of ERK1/2 signaling in the maintenance and survival of RPE 97 
cells, we established a mouse line with an RPE-specific knockout of Erk1 and Erk2 98 
genes (RPE-DKO). Fundus analyses of mice with RPE-specific loss of ERK1/2 99 
showed macular depigmentation. Electroretinogram (ERG) analyses combined with 100 
retinoid measurements revealed dysfunctional vision as well as a significant 101 
decrease in the ocular retinoids content. Optical coherence tomography (OCT) 102 
analyses confirmed the retinal structure disorganization and immunohistochemical 103 
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analyses demonstrated RPE morphology alteration and consequent photoreceptor 104 
(PR) loss. At the onset of retinal degeneration, loss of ERK1/2 led to the specific 105 
decrease of RPE65 with mislocalization of lecithin retinol acyltransferase (LRAT). 106 
The diminution of RPE65 expression depended on the presence of an AP-1 site in 107 
the promoter region, as cFOS and FRA-1 (Fos Related Antigen – 1) protein 108 
expression is decreased and binding to this AP-1 site reduced in RPE-DKO mice. 109 
Results 110 
RPE-specific loss of ERK1/2 causes vision impairment due to the deficit of retinoids. 111 
In order to establish a mouse line with an RPE-specific knockout of Erk1 and Erk2 112 
genes, we used Erk1-/- mice with a conditional allele of Erk2 (Erk1-/-;Erk2f/f) (29) 113 
crossed with transgenic mice carrying the human vitelliform macular dystrophy-2 114 
(VMD2) promoter-directed reverse tetracycline-dependent transactivator (rtTA) and 115 
the tetracycline-responsive element (TRE)-directed Cre (VMD2-rtTA/TRE-Cre) (30), 116 
called RPE-Cre, to obtain VMD2-rtTA/TRE-Cre;Erk1-/-;Erk2f/f mice. Doxycycline 117 
treatment of these mice leads to the disruption of Erk2 specifically in RPE cells. The 118 
VMD2-rtTA/TRE-Cre;Erk1-/-;Erk2∆/∆ (RPE-DKO) line was then compared to Erk1-/-119 
;Erk2f/f as control mice (CTL). 120 
We first analyzed the visual function and retinal structure of RPE-DKO mice in 121 
comparison to CTL mice. Doxycycline (Dox)-induced expression of Cre in RPE cells 122 
was verified by crossing RPE-Cre animals with tdTomato mice (31) to generate RPE-123 
Cre-tdTomato mice. Two intraperitoneal (IP) injections of 10 µg Dox, one week apart, 124 
at 2 months of age triggered consistent expression of Cre specifically in RPE cells 125 
(Fig. 1A). This protocol was followed to induce Cre protein expression in 2 month-old 126 
RPE-DKO mice, while 2 month-old CTL mice were injected with PBS. The genotypes 127 
of all mice were confirmed by PCR amplification of Cre, Erk1 KO and Erk2 floxed 128 
alleles (Fig. 1B and C); deletion of Erk2 in RPE was confirmed by the analysis of 129 
RPE genomic DNA as evidenced by the presence of the delta () band (Fig. 1D). 130 
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Immunostaining shows the decrease of ERK2 in RPE of RPE-DKO at 1 month in 131 
comparison to control mice (Fig. 1E). In addition, Western Blot analysis of RPE 132 
protein lysates clearly shows the absence of ERK1 in both RPE-DKO and CTL mice 133 
and the decrease of ERK2 only in RPE-DKO mouse (Fig. 1F). The fundus analysis 134 
showed apparent depigmentation of RPE-DKO eyes (Fig. 2A). OCT analyses 135 
performed on RPE-DKO at 4 months, revealed degeneration of the retina with a 136 
significant reduction of all retinal and choroidal layers (Fig. 2B). In accordance with 137 
this result, ERG analyses revealed a significant impairment of vision in RPE-DKO at 138 
2 months, as revealed by the lower amplitude of the b wave in both the scotopic and 139 
photopic stimulations (Fig. 2C). Scotopic patterns (50 mcd s/m2) demonstrated the 140 
absence or severe reduction of a and b waves in RPE-DKO mice in comparison to 141 
CTL mice, while photopic patterns (10 mcd s/m2) showed an absence of stimulation 142 
in RPE-DKO mice (Fig. 2C, right panel). This clearly indicates impairment in both the 143 
cone and the rod photoreceptor responses to light stimuli in RPE-DKO animals. 144 
The severe vision damage and retinal degeneration observed in RPE-DKO mice led 145 
us to measure the relative amounts of visual cycle intermediates. Mice that had been 146 
dark-adapted for 12 h were enucleated under dim light. The retina was separated 147 
from the choroid and subjected to HPLC analyses as previously described (32). Loss 148 
of ERK1/2 in the RPE led to a significant decrease of ocular retinoids. Retinyl esters 149 
in the choroid (dissected including the RPE cells) were significantly reduced. In the 150 
retina of dark-adapted eyes, a decrease of more than half of the 11-cis-retinal and 151 
all-trans-retinal was observed (Fig. 2D). We further intended to measure how light 152 
influences the ocular retinoid composition of these mice. Thus, we exposed them to 153 
bright light where the turnover of visual cycle is enhanced. As expected, we observed 154 
an increase of all-trans-retinol and retinyl ester(s) after light treatment. Notably, both 155 
retinoids were significantly lower in RPE-DKO mice when compared to controls, 156 
indicating an impairment of the visual cycle in both dark-adapted and light-exposed 157 
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mice (Fig. 2D). We also noted, by immunostaining analysis, a decrease in the 158 
expression of stimulated by retinoic acid 6 (STRA6) protein, the membrane receptor 159 
for retinol binding protein found in the RPE in RPE-DKO at 1 month (data not shown). 160 
This decrease suggests that a reduction of retinoid uptake from the circulation could 161 
contribute to the diminished ocular retinoid levels in RPE-DKO mice. 162 
RPE-specific loss of ERK1/2 causes a significant thinning of ONL/INL layers 163 
Visual impairment along with retinal dysfunction led us to examine the photoreceptor 164 
structure in RPE-DKO mice. Staining with various cone and rod markers was 165 
performed to analyze the integrity of the distinct retinal layers. Retinal degeneration 166 
was only observed in RPE-DKO mice; as controls, we used ERK1-/-;Erk2f/f mice 167 
treated with PBS (CTL), ERK1-/-;Erk2f/f mice treated with Dox and VMD2-rtTA/TRE-168 
Cre;ERK1-/-;Erk2f/f treated with PBS; none of these mice showed retinal 169 
degeneration (data not shown). No toxic effect of Dox was observed in CTL (data not 170 
shown) or in Cre-tdTomato (Fig. 1A). RPE-DKO mice exhibited a reduction of cone 171 
markers as well as of the outer nuclear layer (ONL) and the inner nuclear layer (INL) 172 
thicknesses. Levels of CONE ARRESTIN and GNAT2 showed a marked decrease in 173 
RPE-DKO mice at 2 months, and this effect was more pronounced at 4 months (Fig. 174 
3A). The important loss of cone markers occurred before the disappearance of 175 
respective rod markers as shown by immunostaining of GNAT2 (Fig. 3A and B). The 176 
rod markers RHODOPSIN and GNAT1 were slightly decreased in RPE-DKO mice, 177 
principally in the ONL. In addition, the outer segment (OS) length is already smaller 178 
in RPE-DKO at 2 months (Fig. 3A). Retinal degeneration could explain the absence 179 
of marked reduction of GNAT1 protein expression shown by Western Blot analysis, 180 
because both GNAT1 and TUBULIN are decreased, so the ratio is not changed. 181 
Measurement of the thickness of ONL and INL layers confirmed a clear decrease in 182 
both cases underlining the devastating effect of ERK1/2 loss in RPE cells (Fig. 3C). 183 
In fact, ONL and INL thickness were reduced by 50 % after only two months of 184 
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ERK1/2 loss and by up to 70 % after 4 months (Fig. 3C). We found staining of both 185 
GNAT1 and CONE-ARRESTIN in RPE of RPE-DKO at 1 month, while no staining 186 
was observed in RPE of control (CTL) mice, as expected (Fig. 3D); this information 187 
supports the hypothesis of a defect in phagocytosis process in these mice. 188 
Interestingly, ONL and INL degenerations correlated with the a level of cell death as 189 
demonstrated by TUNEL assays performed on RPE-DKO and CTL mice (Fig. 3E). 190 
The decrease of the ONL and outer segment (OS) thickness as well as the structural 191 
disorganization of the entire retina was confirmed by electron microscopy (EM) 192 
imaging, revealing the disruption of the inner segment (IS) and OS of photoreceptor 193 
cells (Fig. 4A). This disruption and loss of the OS in particular were quantified by 194 
measuring the ONL, OS and IS lengths (Fig. 4B). A follow-up study of the mice for 195 
one year showed the disappearance of the ONL and a drastic thinning of the INL 196 
layer, with no staining for cones or rods. The only persisting staining was GFAP in 197 
the ganglion cell layer (GCL) and glycine in the inner plexiform layer (IPL) (Fig. 4C).  198 
RPE-specific loss of ERK1/2 causes specific reduction in cone markers 199 
Additional biochemical analyses were carried out in order to verify the loss of cone 200 
photoreceptors. Western blot analysis of retinas from the CTL and RPE-DKO mice 201 
showed that GNAT2, a specific cone marker, was significantly reduced at 2 months 202 
and by more than 60 % at 4 months (Fig. 5A). However, at 4 months, we observed a 203 
marked decrease in both the ONL and INL thickness, which could not only be due to 204 
cone photoreceptor loss. Indeed, at 2 months, the level of GNAT1 is already slightly 205 
affected, while at 4 months the difference is visible even if not significant. At 4 206 
months, the decrease of photoreceptor proteins was mirrored by a reduction in their 207 
mRNA levels. Quantitative PCR (QPCR) showed that specific cone markers, 208 
including Gnat2, ConeArrestin, mOpsin and sOpsin were significantly lowered at 2 209 
months and decreased further by 60-80% at 4 months (Fig. 5B). In agreement with 210 
Western blot studies, the specific rod markers Gnat1 and Rho showed no difference 211 
 
 
9 
at 2 months, but declined at 4 months albeit the reduction was not statistically 212 
significant. Retinal degeneration could explain the absence of significant reduction of 213 
GNAT1 protein expression showed by Western Blot, because both GNAT1 and 214 
TUBULIN are decreased, so the ratio is not changed. 215 
Loss of ERK1/2 in RPE causes RPE ultrastructural damage 216 
Loss of vision as well as pronounced retinal degeneration in these mice prompted us 217 
to examine the state of the RPE ultrastructure in RPE-DKO at 1 month by EM 218 
imaging. An overview of the RPE/retina cell layers showed massive shrinking of the 219 
RPE cell layer, disruption of the Bruch’s membrane (BM) and photoreceptor (PR) 220 
degeneration (Fig. 6A). In order to characterize the damage to the RPE/retinal layer 221 
in more detail, different layers were observed separately and quantified. The BM 222 
ultrastructure was clearly disrupted and the thickness of the membrane was 223 
significantly reduced (Fig. 6B). The RPE cell layer exhibited massive shrinkage as 224 
evidenced by the significant reduction of its length (Fig. 6C). The ultrastructural 225 
damage of the RPE cell layer was accompanied by the accumulation of mitochondria 226 
at the basolateral layer membrane as demonstrated by the significant increase of the 227 
organelles area when normalized to the area of cytosol (Fig. 6C). The RPE cell layer 228 
of RPE-DKO mice contained structures enriched in membranes which resembled 229 
phagolysosomes of the OS of PR (Fig. 6D). This indicates that phagocytosis of OS, 230 
one of the major functions of RPE cells, is impaired in RPE-DKO mice. Confirmation 231 
was obtained by the presence of GNAT1 and CONE-ARRESTIN in the RPE of RPE-232 
DKO at 1 month (Fig. 3D). Ultrastructural analysis demonstrated that the RPE-233 
specific loss of ERK1/2 caused massive alterations to the ultrastructure not only of 234 
the RPE cell layer but also of the BM and the retinal cell layer. The ultrastructural 235 
RPE damage in RPE-DKO mice was confirmed by flatmount RPE-choroid analysis. 236 
Phalloidin staining revealed a disorganized RPE structure along with increased RPE 237 
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cell size including multinucleated cells (Fig. 6E). Total loss of RPE cells was 238 
observed in parts of the retina of RPE-DKO at 2 months (Fig. 6F).  239 
ERK1/2 directly regulate RPE65 levels 240 
We previously showed that inhibition of the ERK1/2 pathway in ARPE19 as well as in 241 
isolated mouse RPE cells leads to a reduction of Rpe65 mRNA expression (9). This 242 
decrease was confirmed by RPE65 immunostaining in RPE-DKO at 1 month or at 2 243 
weeks respectively (Fig. 7A and B). In addition, we observed a mislocalization of 244 
LRAT, the enzyme upstream of RPE65 in the visual cycle, to the apical side of the 245 
RPE cells in RPE-DKO mice instead of the basolateral side as observed in CTL mice 246 
(Fig. 7A and B). QPCR analysis confirmed the results of immunostaining and 247 
revealed that RPE65 but not LRAT expression was significantly decreased in the 248 
RPE cells of RPE-DKO at 1 month (Fig. 7C). RPE65 protein expression, normalized 249 
by TUBULIN, is significantly reduced in RPE-DKO at 1 month (Fig. 7D). Notably, the 250 
promoter of RPE65 has been shown to contain an AP-1 site, which is under 251 
transcriptional control by the AP-1 family of proteins (33). We thus carried out an in 252 
vitro luciferase reporter assay using RPE65 (33) or LRAT (34) promoter constructs. 253 
Luciferase activity was detected with both promoters transfected into the HEK293 cell 254 
line (Fig. 7E). Treatment with the MEK1/2 inhibitor U0126 caused a significant 255 
decrease of the activity of the RPE65 promoter, while no change in activity was 256 
observed when the luciferase reporter is driven by LRAT promoter. Addition of U0126 257 
did not significantly affect the luciferase activity when the AP-1 site in the RPE65 258 
promoter reporter construct was deleted, indicating that it is mandatory for the 259 
regulation by ERK1/2. Next, we set out to identify the downstream effectors of 260 
ERK1/2 that regulate this AP-1 site. Nuclear proteins of ARPE19 cells showed a 261 
strong binding to the AP-1 sequence which was reduced in the presence of a 262 
competitor AP-1 oligonucleotide as well as by treatment with U0126 (Fig. 7F). In 263 
order to identify which factors regulated by ERK1/2 are part of the AP-1 complex, 264 
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nuclear extracts from ARPE19 cells were subjected to an AP-1 ELISA binding assay 265 
that included individual AP-1 family transcription factors. Inhibition of the ERK1/2 266 
pathway in ARPE19 cells, using either U0126 or PD0325901, led to a decrease of c-267 
FOS and FRA-1 protein binding to the AP-1 sequence (Fig. 7F), whereas the 268 
inhibitors had no effect on c-JUN, JUN-B and JUN-D binding (data not shown). In 269 
order to investigate whether this effect is maintained in the RPE-DKO mice, whole 270 
cell protein lysates from isolated RPE cells were subjected to an AP-1 DNA-binding 271 
assay. Indeed, the binding of C-FOS and FRA-1 to AP-1 was significantly reduced 272 
(Fig. 7G) and C-FOS and FRA-1 protein expressions were decreased in RPE of 273 
RPE-DKO mice at 1 month (Fig. 7G). Taken together, the analyses in cell culture and 274 
in the mouse model argue in favor of a direct regulation of RPE65 gene expression 275 
by the ERK1/2 pathway via the binding of C-FOS and FRA-1 complexes to the AP-1 276 
site in the upstream promoter region. 277 
Discussion 278 
In order to evaluate the potential use of ERK1/2 pathway inhibitors in ARMD 279 
treatment and to better understand the ocular side effects observed in cancer 280 
patients treated with such inhibitors, we disrupted ERK1/2 expression specifically in 281 
RPE cells of the mouse.  We observed two major consequences: First, the down-282 
regulation of RPE65, the mislocalization of LRAT and the depletion of the retinoid 283 
content. This already occurrs 1 month after ERK1/2 depletion, when retinal 284 
degeneration just begins to be detected, as shown by chromatin compaction in ONL 285 
cells as well as shortening of photoreceptor OS. Second, changes in the morphology 286 
of the RPE and in the RPE cell death process, which appears later, two months after 287 
Cre induction, when most of the hallmarks of retinal degeneration are visible in the 288 
eyes of RPE-DKO mice.  289 
RPE65 is an enzyme involved in vitamin A metabolism in RPE cells (35).  This key 290 
protein of the visual cycle catalyzes the transformation of all-trans retinyl to 11-cis 291 
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retinol. Mutations in RPE65 are associated with several retinal disorders including 292 
Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA) (36) and early onset 293 
retinal dystrophy (RD) in children (37). Much effort has been devoted to deciphering 294 
the roles of various genetic mutations that are linked to these diseases (38). 295 
However, little is known about how the activity of RPE65 is regulated at the RPE cell 296 
level. Several studies analyzed the promoter region of the RPE65 gene (33, 39) but 297 
little is known about the factors involved in its transcriptional regulation. Retinoic acid 298 
has been suggested to participate to the down-regulation of RPE65 (40) as well as of 299 
fatty acid transporter protein 4 (FATP4) and to the elongation of very long chain fatty 300 
acid protein 1 (ELOVL1) (41). Recently, Masuda and colleagues provided evidence 301 
for an involvement of the sex-determining region Y box containing-gene 9 (SOX9) in 302 
the regulation of the transcription of visual cycle genes, including RPE65, 303 
retinaldehyde binding protein 1 (RBP-1) and retinal G protein-coupled receptor 304 
(RGR). They showed that SOX9 acts synergistically with orthodenticle homeobox 2 305 
(OTX2) to activate RPE65 gene expression (42). Here we identify another critical 306 
upstream regulatory factor for RPE65. We demonstrate that the disruption of ERK1/2 307 
specifically in RPE cells leads to a marked decrease of RPE65 expression that 308 
occurs through an AP-1 site present in the promoter region of the RPE65 gene. The 309 
inhibitory effect of U0126 on reporter gene expression was completely abrogated 310 
when the AP-1 site was removed, even if we cannot exclude that other regulatory 311 
elements close to the AP-1 sequence were also deleted from the construct; this could 312 
explain the low promoter activity observed in absence of AP-1 sequence. The key 313 
roles of cFOS and FRA-1 were confirmed by western blot analysis and by a DNA AP-314 
1 binding assay. Interestingly, ERK1/2 and SOX9 signaling pathways have been 315 
recently shown to interact in urothelial carcinoma (43) and zebrafish sex 316 
determination (44). Moreover, activation of ERK1/2 is associated with an activation of 317 
the Wnt/β-catenin pathway (45, 46), which plays a key role in the expression of RPE-318 
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specific transcription factors microphthalmia-associated transcription factor (MITF) 319 
and OTX2 (47). In conjunction with protein paired box 6 (PAX6), MITF and OTX2 are 320 
key factors of RPE development (48). 321 
ERG combined with the measurement of ocular retinoid levels revealed the impaired 322 
vision of RPE-DKO mice. The significant decrease of retinoids and the histological 323 
evidence of retinal degeneration explain the absence of ERG response in these 324 
mice. The RPE plays a critical role in providing nutrients to the adjacent retina and in 325 
the recycling of the visual chromophore. Upon absorption of light, 11-cis retinal 326 
isomerizes to all-trans retinal in the outer segments of the photoreceptors, and the 327 
RPE is necessary for the subsequent regeneration of the chromophore throughout 328 
the visual cycle (49). The loss of ERK1/2 leads to a decrease in RPE65, and 329 
therefore one would expect retinyl ester(s) to accumulate in the RPE cells as 330 
reported in RPE65 mutant mice (50). However, in RPE-DKO mice we observed a 331 
significant decrease in the retinyl ester(s) both in dark- and light-exposed eyes. 332 
Therefore, in addition to RPE65 down-regulation, which could explain the decrease 333 
of 11-cis retinal, other pathological alterations in the RPE must account for the 334 
decrease in ocular retinoids. We found a mislocalization of LRAT which is mostly 335 
expressed at the apical region of the RPE cells in RPE-DKO mice in comparison to 336 
its normal basolateral localization (51). This mislocalization could affect LRAT activity 337 
and explain the decrease of all-trans retinyl esters. Moreover, we also measured a 338 
lower expression of STRA6, an RPE membrane receptor for the retinol binding 339 
protein responsible for retinyl ester transport. Because STRA6 and LRAT work 340 
together to retrieve retinoids from the blood circulation (52), such diminution may 341 
explain the reduction of retinoid content observed in RPE-DKO mice. These results 342 
phenocopy some of the phenotypes observed in Stra6-/- mice, including low retinoid 343 
content, no ERG response, decrease of BM and RPE lengths, and altered 344 
morphology of RPE cells (53).  345 
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Alteration of the RPE morphology in RPE-DKO is already visible at 1 month. Whole 346 
mounts of RPE from CTL mice show mono- and binucleated hexagonal RPE cells 347 
with an apex shared by three cells, while RPE-DKO mice exhibit unusual RPE 348 
morphology with a total disappearance of the RPE in some parts of the retina two 349 
months after ERK1/2 depletion, whereas other parts display large cells with an 350 
irregular shape and multinucleation (Fig. 6). RPE multinucleation, which has been 351 
reported in humans (54), could result from a cytokinesis defect . The involvement of 352 
cytokinesis defects has been recently described in aging eyes as well as RPE 353 
dysfunctions and RPE cell death (55). As ERK1/2 MAP kinase pathway plays a key 354 
role in cell proliferation, we could envisage that these kinases might be involved in 355 
the process. Sustained activation of ERK1/2 is necessary for the progression from 356 
G1 to S phase and is associated with the up-regulation of proliferation-associated 357 
genes and the down-regulation of anti-proliferative genes (56). Moreover, ERK1/2 358 
signaling is necessary to allow the entry of RPE cells into cell cycling and RPE cell 359 
proliferation (57). In addition to its role in cell cycle control, ERK1/2 are also 360 
implicated in the centrosome orientation (58) which is crucial for cytokinesis. Thus we 361 
can postulate that disruption of ERK1/2 in RPE induces defects in cell cycle 362 
progression, leading to multinucleation of RPE first and then to RPE cell death. 363 
Whereas central RPE cells are senescent, the peripheral cells proliferate and 364 
ERK1/2 could be important for their maintenance (59, 60). Retinal regeneration in the 365 
chick embryo was shown to be dependent on FGF/FGFR/MEK/ERK-dependent 366 
upregulation of PAX6 (25). Activation of the ERK1/2 pathway was also responsible 367 
for the 15-deoxy-Δ12,14-prostaglandin J2 (dPGJ2)-dependent protection of RPE cells 368 
from oxidative injury (61). These data point not only to a protective role of the ERK1/2 369 
pathway in RPE cells but also to their participation in the maintenance and 370 
proliferation of these cells, at least in the peripheral region. Our data indicate that 371 
ablation of ERK1/2 in 2 month-old adult RPE cells almost completely abrogated 372 
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vision by initiating an early cone-specific degeneration, followed by rod impairment.  373 
Surprisingly, we observed a decrease of GNAT1 immunostaining in Cre-DKO mice at 374 
2 and 4 months, which is not observed either by qPCR or Western Blot analysis. At 375 
the same time, we clearly detected a decrease in ONL length and thus even if the 376 
total GNAT1 retinal content decreases, the TUBULIN abundance decreases in 377 
parallel, so that the GNAT1/TUBULIN ratio is not modified. One outstanding question 378 
is why are cones more affected than rods in this model? The dependence of cone PR 379 
survival on RPE65 has already been reported (62), therefore the direct regulation of 380 
RPE65 by ERK1/2 could account, at least in part, for the severe cone dystrophy 381 
found in RPE-DKO mice. Moreover, inadequate 11-cis retinal production has been 382 
shown to be associated with cone degeneration, although the mechanisms are 383 
currently not well understood (63-65). The measurement of retinoids specifically in 384 
the retina of RPE-DKO mice revealed a significant decrease in 11-cis-retinal, which 385 
could contribute to the rapid cone degeneration. This finding suggests that the cone-386 
specific effect seen at 2 months could be directly attributed to the ERK1/2 role in 387 
regulating RPE65 activity and 11-cis-retinal production that are critical for cone PR 388 
survival. 389 
Earlier observations demonstrated that PR degeneration in Rpe65-/- mice caused 390 
massive activation of ERK1/2 in the GCL of the retina (23), probably in order to 391 
protect the retina against the stress induced by the absence of RPE65. However, we 392 
recently showed in polarized ARPE19 cells and isolated mouse RPE that A2E 393 
treatment decreases phospho-ERK1/2 significantly along with a reduction of RPE65 394 
level. In addition, inhibition of the ERK1/2 pathway by U0126 also induces a 395 
significant decrease of RPE65 expression (9). The role of ERK1/2 in RPE cells has 396 
not been subject to detailed investigation. Our study showing that ERK1/2 loss leads 397 
to RPE cell death, retinal atrophy and degeneration strongly supports a significant 398 
role for ERK1/2 in the maintenance and survival of RPE cells. Defects of RPE cells 399 
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and RPE cells death will lead to PR degeneration. Consistently, these features were 400 
observed in a mouse model of genetic RPE ablation that expressed an inducible 401 
diphtheria toxin A (DTA) specifically in the RPE. In this RPECreER/DTA model, 402 
functional analysis showed very low scotopic and photopic ERG responses as well 403 
as PR degeneration (66). Accordingly, interactions of PR with RPE are essential for 404 
PR survival (67). 405 
The very rapid INL degeneration observed in RPE-DKO mice is more difficult to 406 
explain. Even if the Cre expression is observed specifically in RPE cells, as shown in 407 
the Cre-tdTomato mice (Fig. 1) and as previously described (30), we also noted in 408 
certain mice an ectopic expression of Cre in the IPL vessels (but not in the choroidal 409 
vessels). Therefore, we cannot totally exclude that ERK1/2 was also depleted in 410 
some IPL vessels that may impact on INL degeneration. We can also hypothesize 411 
that the absence of key factors normally secreted by the RPE may influence INL 412 
degeneration. Further analyses are required in order to decipher the mechanisms 413 
leading to INL degeneration in ERK1/2-depleted mice. 414 
Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy but 415 
some of these early-phase trials were stopped prematurely because of toxicity 416 
issues, including various ocular adverse effects (21, 68-70). Treatments last 417 
approximatively 3 weeks and are repeated every month (71, 72). Such long-term 418 
treatment with multiple dosing of highly potent MEK inhibitors will lead to a marked 419 
and sustained inhibition of ERK1/2 activity, phenocopying in part the impact of the 420 
double knockout. We already observed a significant decrease of RPE65 expression 421 
at 2 weeks (Fig. 7B) while mRNA and protein levels of this RPE marker are 422 
decreased by about 50% at 1 month (Fig. 7C and 7D). Our study provides evidence 423 
for a key role of ERK1/2 signaling within the eye and more specifically in RPE cells. 424 
Ablation of ERK1/2 signaling reduces RPE65 expression, leads to decreased retinoid 425 
levels, affects RPE and retinal structure, and induces retinal degeneration. Therefore, 426 
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the use of ERK1/2 pathway inhibitors in ARMD treatment, as recently suggested 427 
(26), has to be re-evaluated taking into consideration the findings reported here. 428 
Fine-tuning in ERK1/2 inhibition will be necessary in order to only block the negative 429 
effects of high kinase activity and restore low ERK1/2 activity without impacting the 430 
role of this kinase in RPE cells. 431 
Materials and methods 432 
Animals 433 
The studies involving mice adhered to the Association for Research in Vision 434 
and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and 435 
vision research and were approved (permit number VD3023) by the Veterinary 436 
service of the State of Vaud (Switzerland). Animals were maintained in 12-h light / 437 
12-h dark cycle with unlimited access to food and water. The generation of Erk1-/-438 
/Erk2fl/fl has been reported previously (29). RPE-specific loss of ERK1/2 (VMD2-439 
rtTA/TRE-Cre;Erk1-/-;Erk2/ : RPE-DKO) was created by cross-breeding the Erk1-/-440 
/Erk2f/f mouse with a mouse expressing the Cre recombinase driven by the human 441 
vitelliform macular dystrophy-2 (VMD2) [RPE-Cre] promoter and inducible by 442 
doxycycline (30) to first obtain VMD2-rtTA/TRE-Cre;Erk1-/-; Erk2f/f. Then two months 443 
after birth, VMD2-rtTA/TRE-Cre;Erk1-/-;Erk2f/f mice were injected twice, one week 444 
apart, with 10ug of doxycycline (Dox) in 500ul PBS in order to induce the Cre 445 
recombinase; we call these mice RPE-DKO. As control, Erk1-/-/Erk2f/f mice were 446 
injected in a similar way with PBS; we call these mice CTL. Every time period 447 
mentioned in the experiments refers to the amount of time after Dox injection (e.g. 448 
RPE-DKO at 2 months is a 4 month-old mouse treated after 2 months and analyzed 449 
2 months later, after Cre induction and ERK1/2 depletion). Cre-tdTomato mice were 450 
created by crossbreeding VMD2-rtTA/TRE-Cre with tdTomato (31) mice to setup the 451 
Dox injection protocol and visualize Cre expression. Genotyping of mice was carried 452 
out using PCR analysis with genomic DNA isolated from ear punches (Direct PCR 453 
 
 
18 
(Ear), Viagen). All the mice were verified for mutant Rd1 negative genotype. The 454 
mice were processed for fundus analysis, OCT and ERG or sacrificed for other 455 
functional assays at 2w, 1m, 2m, 4m or 1y after the second injection. 456 
Cell culture 457 
HEK293T cells were cultured in high glucose DMEM containing 25 mM of HEPES. 458 
The cells were passed every 2-3 days. 600 K cells were seeded in a P60 plate and 459 
transfected after 24 hours using calcium-phosphate transfection kit (GE Healthcare) 460 
with indicated plasmids, according to the manufacturer’s instructions. When indicated 461 
cells were treated with 10 nM U0126 (Cell Signaling Technology) or 2 μM PD0325901 462 
(Cell Signaling Technology) for 24 hours and lysed with lysis buffer (20 mM MOPS 463 
pH 7.0, 2mM EGTA, 5mM EDTA, 30mM Sodium Fluoride, 60 mM β-464 
Glycerophosphate pH 7.2, 20 mM Sodium Pyrophosphate, 1 mM Sodium 465 
Orthovanadate, 1 % Triton-X 100) before analysis. 466 
Non-invasive experiments 467 
Mice were anaesthetized by IP injection of Xylazine 10 mg/kg + Ketamine 80 mg/kg. 468 
Mydriatic agents (tropicamide 0.5 %, 2 min; phenylephrine hydrochloride 10 %, 1 469 
min) were applied on the eye for the pupil dilation and to block the eyebrow 470 
movement. The fundus of age-matched CTL and RPE-DKO were photographed. 471 
OCT was carried out in age-matched CTL and RPE-DKO mice using OCT system 472 
(Micron III, Phoenix Research Laboratories) according to the manufacturer’s 473 
recommendation, at 4 months and 1 year. 474 
For scotopic ERG, age-matched CTL and RPE-DKO mice were dark-adapted 475 
overnight before anesthesia and application of the mydriatic agents as described 476 
above. For photopic ERG, mice were exposed to bright light of 1000 mAH for 10 477 
minutes. Full-field ERG was recorded using the HMsERG system (Ocuscience). 478 
Immunohistochemistry 479 
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Enucleated eyes were fixed in 4% PFA/PBS for 45 min, followed by cryoprotection in 480 
30% sucrose/PBS. 10 µm-embedded frozen sections were further processed for 481 
immunohistochemistry. Briefly, frozen retina sections were blocked in PBS with 3% 482 
normal goat serum (Sigma-Aldrich) and 0.2% Triton X-100 (Sigma-Aldrich) for 1 h at 483 
RT and incubated with primary antibodies in the blocking buffer overnight at 4°C. The 484 
following primary antibodies were used: ConeArrestin (Merck Millipore), Rhodopsin 485 
(Rho 1D4, a kind gift of Dr. Robert J. Moldy), mOpsin (Chemicon), STRA6 (Abcam), 486 
GNAT1 (Santa Cruz Biotechnology), GNAT2 (Santa Cruz Biotechnology), RPE65 487 
(Pin5, a kind gift of Andreas Wenzel), LRAT (Santa Cruz Biotechnology), GFAP 488 
(Chemicon), Glycine (ImmunoSolution). Sections were incubated again in blocking 489 
buffer for 30 min at RT before incubating with the secondary antibodies for 1 h at RT. 490 
Secondary or fluorescent labeled antibodies were: Goat anti-Mouse Alexa Fluor® 491 
488 conjugate, Goat anti-Mouse Alexa Fluor® 594 conjugate, Goat anti -492 
Rabbit Alexa Fluor® 488 conjugate, Goat anti-Rabbit Alexa Fluor® 594 493 
conjugate, Oregon Green® 488 Phalloidin (Thermo Fisher Scientific). 494 
Incubation with secondary antibody alone was used as a negative control. Tissue 495 
sections were counterstained with DAPI to identify retinal cell layers.  496 
For flatmount choroid-RPE structure, dissected choroid-RPE sections were mounted 497 
on a cover slip, fixed in 4% PFA/PBS for 45 min and processed for immune labeling 498 
with Oregon as described. TUNEL assay (Roche Life Science) was carried out as 499 
already described (23). 500 
Tissue isolation, mRNA extraction and protein preparation 501 
Enucleated eyes from CTL and RPE-DKO were dissected under a microscope to 502 
exclude extra-ocular tissues. The cornea, lens, iris, and vitreous body were removed 503 
and the retina extracted. Either the retina, the RPE or the RPE-choroid were 504 
processed for protein/mRNA isolation. 505 
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For mRNA extraction, either the retina or the RPE-choroid were resuspended in 506 
TRIzol (TRIzol® Reagent, ThermoFisher) and stored at -80 °C until further 507 
handling. RPE mRNA was extracted using a previously described protocol (73), while 508 
retinas and RPE-choroids were extracted using the following protocol. Briefly, 0.1 509 
volume of sodium acetate, 1 volume of phenol and 0.2 volume of chloroform were 510 
added to the tube, mixed and phase separation was allowed on ice for 15 minutes. 1 511 
volume of isopropanol and 2 µl of glycogen (5 µg/µl) were added to the upper 512 
aqueous phase and left to precipitate at -200C overnight. Following centrifugation at 513 
10,000g for 10 min at 40C, the precipitate was washed with 75 % EtOH, and allowed 514 
to dry at RT before being resuspended in ddH2O DEPC. Quantitative PCR was 515 
carried out as already described (23) using 100 nM primers. The sets of primers used 516 
for genotyping (Fig. 1B) and RT-PCR can be found in table 1. 517 
Protein isolation from retinas was performed by two successive homogenizations of 518 
the retina with syringes (23G and 26G) on ice, followed by 3 freeze/thaw cycles. RPE 519 
cell lysates were prepared as previously described (74). Briefly, incised RPE/Choroid 520 
was incubated in RIPA (50mM Tris pH8.0, 150mM NaCl, 1% NP-40, 0.5% sodium 521 
deoxycholate, 0.1% SDS) buffer for 10 min with shaking. The choroid was transferred 522 
to a different tube leaving the shredded RPE cells on the tube wall. 523 
For western blot analysis, extracted retinas were resuspended in lysis buffer (20mM 524 
MOPS pH7.0, 2mM EGTA, 5mM EDTA, 30 mM sodium fluoride, 60 mM-B-525 
gylcerophosphate pH7.2, 20mM sodium pyrophosphate, 1mM sodium 526 
orthovanadate, 1% TritonX-100, DTT 1M + protease inhibitors) while RPE were 527 
resuspended in RIPA buffer (50mM Tris pH8.0, 150mM NaCl, 1% NP-40, 0.5% 528 
sodium deoxycholate, 0.1% SDS). All samples were conserved at -80 0C until further 529 
processed. Extracted cell lysates were separated by SDS–PAGE and transferred 530 
onto nitrocellulose membranes (Millipore). The membranes were probed using the 531 
indicated primary antibodies and isotype-matched secondary antibodies conjugated 532 
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to fluorescence (Licor Biosciences) and detected using the Odyssey imaging system 533 
(Licor). The following primary antibodies were utilized: GNAT 1 (Santa Cruz 534 
Biotechnology), GNAT2 (Santa Cruz Biotechnology), ERK1/2 (Cell Signaling 535 
Technology), -TUBULIN (Sigma-Aldrich), RPE65 (Pin5). Following secondary 536 
bodies were applied: IRDye 680RD (LI-COR Biosciences), IRDye 800CW (LI-COR 537 
Biosciences). 538 
Luciferase and AP-1 binding assays 539 
Luciferase activity was measured in cell lysates using a coenzyme A-coupled assay 540 
system containing luciferin and ATP (Promega). Ten µg of cell lysates were mixed 541 
with 20 µl of luciferase assay reagent in 4 triplicates. Lum/E was read using a kinetic 542 
software on a 384 well plate spectrophotometer (PerkinElmer). Βeta-galactosidase 543 
activity was measured using a luminescent substrate endpoint assay. 20 µg of 544 
lysates were mixed with 50 µl β-gal buffer 2x (Na2HPO4 120 mM, NaH2PO4 80 mM, 545 
MgCl2 2 mM and β-ME 100 mM) and 50 µl ONPG 2x (2-Nitrophenyl-B-D-546 
Galactopyranoside). The absorbance at 412 nm was read. 547 
AP-1 binding assay (TransAM AP-1 kit, Active Motif) was carried out as described 548 
(24) on nuclear extracts from ARPE19 cells. Briefly, cells were resuspended in 1 ml 549 
cold buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 1 mM DTT and protease inhibitors) 550 
and placed for 15 min on ice. Then 12.5 μl of 10% NP-40 was added and the 551 
supernatant was discarded after centrifugation. Nuclei were lysed in buffer B (20 mM 552 
Hepes, pH 7.9, 400 mM NaCl, 1 mM DTT and protease inhibitors) and quantified for 553 
protein content. 8 µg of nuclear protein extract or 15 µg of whole cell protein extracts 554 
were used for AP-1 binding assay as described by the manufacturer. 555 
AP-1 EMSA Assay 556 
AP-1 EMSA assay was carried out on nuclear extracts from HEK293 cells either left 557 
untreated or treated with U0126 following the protocol of the provider (Odyssey® 558 
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Infrared EMSA Kit, LI-COR Biosciences). In brief, the nuclear extract was incubated 559 
with 25 mM DTT/2.5% Tween-20, 1 µg/µl Ploy (dl.dc), 1% NP-40, 100 mM MgCl2, 560 
IRDye 700 AP-1 Consensus Oligo (5’-CGCTTG ATG ACT CAG CCG GAA-3’) either 561 
in the presence or absence of AP-1 competitor oligo. The binding was performed for 562 
20 minutes after which the sample was loaded on a 5% Native Acrylamid gel in the 563 
presence of a loading dye. The fluorescence was detected on LI-COR Odyssey 564 
scanner. 565 
Retinoid measurement 566 
Age-matched CTL and RPE-DKO mice were either dark-adapted overnight or 567 
exposed to bright light of 1000 mAH for 2 hours. For the dark condition, the retina 568 
was separated from the RPE-choroid layer. For the bright light condition, the whole 569 
eye was processed for the measurement. Ocular tissues were transferred into a 2 ml 570 
reaction vial and 200 µl of 2 M hydroxylamine (pH 6.8) and 200 µl of methanol were 571 
added. All steps were conducted under red safety light (> 600 nm) to avoid retinoid 572 
isomerization. Tissues were mechanically grinded using a Bio-Gen PRO200 573 
homogenizer (Fisher Scientific). The homogenized extracts were allowed to stand for 574 
10 min for oxime formation. Then, 400 µl of acetone and 500 µl of hexane were 575 
added. The samples were vortexed and the aqueous and organic phases were 576 
separated by centrifugation at 5,000 x g (Eppendorf Minispin plus). The organic 577 
phase was removed and the extraction was repeated with 500 µl of hexane. 578 
Collected organic phases were pooled and dried with a SpeedVac (Eppendorf) at 579 
30oC and re-dissolved in HPLC mobile phase solvent. The HPLC analysis was 580 
carried out with an Agilent 1260 Infinity Quaternary HPLC system (Santa Clara) 581 
equipped with a pump (G1312C) with an integrated degasser (G1322A), a 582 
thermostated column compartment (G1316A), an autosampler (G1329B), a diode-583 
array detector (G1315D), and online analysis software (Chemstation). The analyses 584 
were carried out at 25oC using a normal-phase Zorbax Sil (5 μm, 4.6 x 150 mm) 585 
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column (Agilent Technologies) protected with a guard column with the same 586 
stationary phase. For retinoid separation, the column was developed with 90% 587 
hexane and 10% ethyl acetate with an isocratic flow rate of 1.4 ml x min-1. For molar 588 
quantification of retinoids the HPLC system was scaled with authentic retinoid 589 
standards.  590 
Electron Microscopy 591 
Enucleated whole mouse eyes were fixed in glutaraldehyde solution (Electron 592 
Microscopy Sciences) 2.5% in Phosphate Buffer (PB 0.1M pH7.4) (Sigma-Aldrich) for 593 
90 min at room temperature (RT). Then, ocular tissues were post-fixed by a fresh 594 
mixture of osmium tetroxide 1% (Electron Microscopy Sciences) with 1.5% of 595 
potassium ferrocyanide (Sigma-Aldrich) in PB buffer during 1h30 at RT. The samples 596 
were then washed three times in distilled water and dehydrated in graded 597 
concentrations of acetone solution (Sigma-Aldrich) (30%-20min; 70%-20min; 100%-598 
1h; 100%-2h). This was followed by infiltration in graded concentrations of Epon 599 
(Sigma-Aldrich) (2h Epon-acetone: 1/3; 2h Epon-acetone: 3/1; 4h and 12h Epon-600 
acetone: 1/1) and finally polymerized for 48h at 60°C in an oven. Ultrathin sections of 601 
50nm were cut transversally on a Leica Ultracut (Leica Microsystems) and picked up 602 
on a nickel slot grid 2x1mm (Electron Microscopy Sciences) coated with a 603 
polystyrene film (Sigma-Aldrich). Sections were post-stained with uranyl acetate 604 
(Sigma-Aldrich) 4% in H2O during 10 minutes, rinsed several times with H2O followed 605 
by Reynold’s (Reynolds ES. 1963. J Cell Biol, 17, 208-212) lead citrate 0.4% in H2O 606 
(Sigma-Aldrich) during 10 minutes and rinsed several times with H2O. 607 
Micrographs were taken with a transmission electron microscope Philips CM100 608 
(now FEI Company) at an acceleration voltage of 80kV with a TVIPS TemCam-F416 609 
digital camera (TVIPS GmbH). 610 
Molecular biology 611 
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pGL2-Basic-RPE65 (-450/+39) was a kind gift of Dr. Debra Thompson (University of 612 
Michigan). pGL3-Basic-LRAT (-268/+257) was a kind gift of Dr. Catharine Ross 613 
(University of Pennsylvania). pGL2-Basic-RPE65 (-450/+39) (33) was digested by 614 
BglII and StuI and re-ligated in order to remove the (190 bp segment from the start 615 
codon) AP-1 site. 616 
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Figure Legends 843 
Fig. 1: Generation and characterization of CTL and RPE-DKO mice. (A) 844 
tdTomato fluorescence of the cryostat section of a fixed whole mount eye from 845 
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Cre/tdTomato mice injected with either PBS or doxycycline (Dox). (B) Constructs 846 
used to generate the Erk1-KO and Erk2 conditional mice (Erk1-/-Erk2f/f) and primers 847 
used to genotype the mice. (C) Representative genotyping of Erk1+/-;Erk2+/f (lane 1), 848 
Erk1-/-;Erk2f/f called CTL (lane 2) and VMD2-rtTA/TRE-Cre;Erk1-/-;Erk2lx/lx called RPE-849 
DKO, when injected with Dox (lane 3). (D) The specific loss of Erk2 in RPE is 850 
confirmed by the delta fragment present in genomic DNA isolated from RPE cells; 851 
Erk1+/-;Erk2+/f (lane 1), Erk1-/-;Erk2f/f called CTL (lane 2) and VMD2-rtTA/TRE-852 
Cre;Erk1-/-;Erk2lx/lx called RPE-DKO, when injected with Dox (lane 3). (E) Cryostat 853 
section of fixed whole mount eyes, from CTL and RPE-DKO at 1 month, 854 
immunostained as indicated. (F) Western blot analysis of ERK1/2 expression in RPE 855 
protein lysates from CTL and RPE-DKO at 1 month; ARPE19 protein lysate is used 856 
as positive control for ERK1 expression. 857 
Fig. 2: Loss of ERK1/2 in RPE leads to vision impairment. (A) Representative 858 
fundus images of CTL and RPE-DKO at 2 or 4 months. (B) Representative OCT 859 
images of CTL and RPE-DKO at 4 months. (C) Graphs of the scotopic (n=10) and 860 
photopic (n=4) ERG responses (b wave) taken in CTL and RPE-DKO at 2 months. 861 
(*p<0.05, **p<0.001). The right panel shows the scotopic (50 mcd s/m2) and the 862 
photopic (10 mcd s/m2) ERG response of CTL and RPE-DKO mice. (D) 863 
Chromatographs and quantification of retinoids measured in the retina and in the 864 
RPE/choroid from mice at 1 month, dark-adapted for 16 hours or measured in whole 865 
eye (containing retina, RPE and choroid) from mice (same conditions) exposed to 866 
1000 mA of light for 2 hours. 867 
Fig. 3: Loss of ERK1/2 in RPE leads to photoreceptor degeneration. (A) Cryostat 868 
section of fixed whole mount eye, from CTL and RPE-DKO at 2 or 4 months, 869 
immunostained against different rod and cone markers as indicated. (B) Flatmount 870 
retinal preparation, from CTL and RPE-DKO at 4 months, immunostained as 871 
indicated. (C) Outer nuclear layer (ONL) and inner nuclear layer (INL) lengths 872 
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measured manually using ImageJ. Data represent mean ± SEM of four independent 873 
experiments *p<0.05. (D) GNAT1 and ConeArrestin stainings from CTL and RPE-874 
DKO at 1 month. Presence of both photoreceptor markers was observed in the RPE 875 
of RPE-DKO mice (white arrows). (E) TUNEL staining of cryostat section of fixed 876 
whole mount eye from CTL and RPE-DKO at 2 months. 877 
Fig. 4: Outer nuclear layer (ONL), outer segment (OS) and inner segment (IS) 878 
decrease from the start of degeneration to complete absence in RPE-DKO at 1 879 
year. (A) Electron microscopy images of retina-RPE layers from CTL and RPE-DKO 880 
at 2 or 4 months. The bottom panel is a magnification of outer segment (OS) layer of 881 
photoreceptors (PR). (B) Measurement of outer nuclear layer (ONL), outer segment 882 
(OS) and inner segment (IS) from electron microscopy images. Data represent mean 883 
± SEM of 3 experiments, **p<0.008. (C) Cryostat section of fixed whole mount eye, 884 
from CTL and RPE-DKO at 1 year, immunostained as indicated. 885 
Fig. 5: Loss of ERK1/2 in RPE causes specific reduction in cone markers. (A) 886 
Representative images and quantification graphs of retinal protein lysates from CTL 887 
and RPE-DKO at 1, 2 or 4 months. Data represent mean ± SEM of 5 independent 888 
experiments (*p<0.02, **p<0.001). (B) Quantification graphs of QPCR performed on 889 
retinal extracts from CTL and RPE-DKO at 1, 2 or 4 months. RL8 was used as 890 
internal control to normalize RNA expression. Results are expressed as percentage 891 
of CTL and as mean ± SEM of 4 independent experiments (*p<0.05, **p<0.003). 892 
Fig. 6: Loss of ERK1/2 in RPE leads to massive ultrastructural changes in RPE-893 
DKO at 1 month. (A) Representative electron microscopy images showing different 894 
retinal and RPE cell layers (B, Bruch’s Membrane; RPE, Retinal Pigment Epithelium; 895 
OS, Outer Segment; IS, Inner Segment; ONL, Outer Nuclear Layer). (B) 896 
Representative electron microscopy image of the Bruch’s membrane (B, Bruch’s 897 
membrane) and the underlying RPE cells and measurement of Bruch’s membrane 898 
length (*p<0.0001). (C) Representative electron microscopy image of the RPE cell 899 
 
 
35 
layer and the underlying OS of the PR, and measurement of RPE length and 900 
quantification of the area of mitochondria (stars: mitochondria) (*p<0.015). (D) 901 
Electron microscopy image showing the accumulation of membrane-enriched 902 
phagolysosomes in the RPE of RPE-DKO in comparison to CTL (white arrows). (E 903 
and F) RPE flatmount from CTL and RPE-DKO at 2 months, immunostained against 904 
Phalloidin and counterstained with Dapi. 905 
Fig. 7: ERK1/2 directly regulates RPE65 expression. (A) Cryostat section of fixed 906 
whole mount eyes, from CTL and RPE-DKO at 1 month, immunostained as 907 
indicated. (B) Cryostat section of fixed whole mount eyes, from CTL and RPE-DKO 908 
at 2 weeks, immunostained as indicated. (C) QPCR analysis of mRNA extracted from 909 
the RPE/choroid of CTL and RPE-DKO at 1 month, for the genes indicated. RL8 was 910 
used as internal control to normalize RNA expression. Results are expressed as 911 
percentage of CTL and as mean ± SEM of 3 retinas, *p<0.03. (D) Representative 912 
immunoblot and quantification of RPE protein lysates from CTL and RPE-DKO at 1 913 
month, immunoblotted as indicated, **p<0.0002, n=5. (E) Luciferase assay for both 914 
RPE65 and LRAT promoters. HEK293 cells were transfected and treated as 915 
indicated. The luciferase fluorescence was normalized to β-gal fluorescence. Data 916 
represent mean ± SEM of 4 independent experiments, *p<0.05 vs pGL2-Basic-917 
RPE65, #p<0.05 vs pGL2-Basic. (F) EMSA assay of AP-1 complex in nucleus from 918 
ARPE19 cells treated or not with U0126.  AP-1 DNA binding analysis from nuclear 919 
extract of ARPE19 cells treated either with U0126 or PD0325901. Data represent 920 
mean ± SEM of 3 independent experiments expressed as percentage of control, 921 
*p<0.02, **p<0.002. (G) AP-1 DNA binding analysis of whole cell extracts from mice 922 
at 1 month. Data represent mean ± SEM of 3 independent experiments expressed as 923 
percentage of control, *p<0.015, **p<0.002, n=6. Representative immunoblot of RPE 924 
protein lysates from CTL and RPE-DKO at 1 month, showing the expression of C-925 
FOS and FRA-1; TUBULIN was used as control. 926 
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Table 1: Primers used for genotyping and qPCR 927 
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Table 1  
The following primer sets were used: 
Purpose Genes  Primers 
Genotype 
Erk2 
B GCCTTCCAACCTCCTGCTGAACACC 
Wt GCACCTAACAAAGCTTCACCCAGG 
D AAGCTTGAGCTCCTCGAGAGATCGGC 
D1 GTACTGGATCCGAGCTCATAACTTCG  
D2 GGGATCAGCTTCAACCTTGCTGGG  
Erk1 
A GAAGGAGCCAAGCTGCTATT 
C AGCAATGACCACATCTGCTA 
K AACGTGTGGCTACGTACT 
Cre 
R CTAATCGCCATCTTCCAGCAGG 
F AGGTGTAGAGAAGGCACTTAGC 
rTtA 
R TCAAACTCGAAGTCGGCCATATCC 
F CGGCCTTGAATTGATCATATGCGG 
QPCR 
Gnat1 
R ACTGAATGTTGAGGTGGTC 
F AGAGGATGCTGAGAAGGATG 
Gnat2 
R GACTTGAACTCTAGGCACTC 
F CATCAGTGCTGAGGACAAAG 
sOpsin 
R AGGGCCAACTTTGCTAGAAG 
F TGGTCAACAATCGGAACCAC 
mOpsin 
R GGCGCAGCTTCTTGAATCTC 
F TGAGGATAGCACCCATGCAA 
Rpe65 
R AAAGCACAGGTGCCAAATTC 
F CCCTCCTGCACAAGTTTGAC 
mRl8 
R GCTTCACTCGAGTCTTCTTG 
F ACTGGACAGTTCGTGTACTG 
Lrat 
R GACAGCCGAAGCAAGACTGCT 
F ACGCAGAGCTGAGCAGCAGTT 
ConeArr 
R AGTTGTCCAGACCACAGATG 
F TTGTGCTAGAGGCCAGATTG 
 
